Stevanato Group S.p.A. (STVN)
NYSE: STVN · Real-Time Price · USD
23.48
-0.52 (-2.17%)
Jun 13, 2025, 4:00 PM - Market closed
Revenue by Product
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2019 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2019 - 2020 |
| Biopharmaceutical and Diagnostic Solutions | 955.66M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Biopharmaceutical and Diagnostic Solutions Growth | 8.27% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Engineering | 168.98M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Engineering Growth | -15.80% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBIT by Product
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2019 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2019 - 2020 |
| Biopharmaceutical and Diagnostic Solutions Operating Profit | 178.99M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Biopharmaceutical and Diagnostic Solutions Operating Profit Growth | 1.11% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Engineering Operating Profit | 31.57M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Engineering Operating Profit Growth | -29.51% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Eliminations from Operating Profit | -40.08M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Eliminations from Operating Profit Growth | 9.98% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Gross Income by Product
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2019 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2019 - 2020 |
| Biopharmaceutical and Diagnostic Solutions Gross Profit | 283.96M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Biopharmaceutical and Diagnostic Solutions Gross Profit Growth | 28.08% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Engineering Gross Profit | 51.13M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Engineering Gross Profit Growth | -37.68% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Eliminations from Gross Profit | -25.08M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Eliminations from Gross Profit Growth | 46.63% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2019 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2019 - 2020 |
| EMEA | 682.11M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| EMEA Growth | 9.15% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| APAC | 97.77M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| APAC Growth | 1.04% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| North America | 314.90M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| North America Growth | -4.55% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| South America | 29.87M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| South America Growth | -6.05% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2018 - 2019 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2018 - 2019 |
| Backlog |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Backlog Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|